{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:44:23Z","timestamp":1784839463915,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T00:00:00Z","timestamp":1535414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","brainanddevelopment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.braindev.2018.07.003","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T11:35:15Z","timestamp":1532691315000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan"],"prefix":"10.1016","volume":"41","author":[{"given":"Masashi","family":"Mizuguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9649-9499","authenticated-orcid":false,"given":"Kuriko","family":"Kagitani-Shimono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harumi","family":"Yoshinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masae","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Yonemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.braindev.2018.07.003_b0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","article-title":"Neurological and neuropsychiatric aspects of tuberous sclerosis complex","volume":"14","author":"Curatolo","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.braindev.2018.07.003_b0010","first-page":"2021","article-title":"Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options","volume":"10","author":"Wang","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.braindev.2018.07.003_b0015","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0883073810361789","article-title":"Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment","volume":"25","author":"Curatolo","year":"2010","journal-title":"J Child Neurol"},{"key":"10.1016\/j.braindev.2018.07.003_b0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13023-015-0371-1","article-title":"Autism spectrum disorder in tuberous sclerosis complex: searching for risk markers","volume":"10","author":"Vignoli","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2018.07.003_b0025","doi-asserted-by":"crossref","unstructured":"Stafstrom CE, Hagerman PJ, Pessah IN. Pathophysiology of epilepsy in autism spectrum disorders. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies. Bethesda MD: Michael A Rogawski, Antonio V Delgado-Escueta, Jeffrey L Noebels, Massimo Avoli and Richard W Olsen; 2012.","DOI":"10.1093\/med\/9780199746545.003.0071"},{"key":"10.1016\/j.braindev.2018.07.003_b0030","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2018.07.003_b0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1528-1167.2009.02341.x","article-title":"Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies","volume":"51","author":"Wong","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.braindev.2018.07.003_b0040","first-page":"18","article-title":"Treatment of autism spectrum disorder in children and adolescents","volume":"46","author":"DeFilippis","year":"2016","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.braindev.2018.07.003_b0045","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2174\/1871527315666160413120638","article-title":"mTOR, a potential target to treat autism spectrum disorder","volume":"15","author":"Sato","year":"2016","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.braindev.2018.07.003_b0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jns.2013.05.029","article-title":"Role of the mTOR signaling pathway in epilepsy","volume":"332","author":"Meng","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.braindev.2018.07.003_b0055","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/ncomms2295","article-title":"Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex","volume":"3","author":"Sato","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.braindev.2018.07.003_b0060","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1212\/WNL.0b013e3181e04325","article-title":"Biallelic TSC gene inactivation in tuberous sclerosis complex","volume":"74","author":"Crino","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.braindev.2018.07.003_b0065","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.braindev.2018.07.003_b0070","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.braindev.2018.07.003_b0075","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpeds.2013.12.053","article-title":"Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex","volume":"164","author":"Cardamone","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.braindev.2018.07.003_b0080","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0883073808324535","article-title":"Rapamycin reduces seizure frequency in tuberous sclerosis complex","volume":"24","author":"Muncy","year":"2009","journal-title":"J Child Neurol"},{"issue":"4","key":"10.1016\/j.braindev.2018.07.003_b0085","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1089\/cap.2016.0100","article-title":"Beneficial effects of everolimus on autism and attention-deficit\/hyperactivity disorder symptoms in a group of patients with tuberous sclerosis complex","volume":"27","author":"Kilincaslan","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.braindev.2018.07.003_b0090","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.braindev.2018.07.003_b0095","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1177\/088307389801301206","article-title":"Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria","volume":"13","author":"Roach","year":"1998","journal-title":"J Child Neurol"},{"key":"10.1016\/j.braindev.2018.07.003_b0100","unstructured":"National Cancer Institute. Common terminology criteria for adverse events, (CTCAE), version 4.03. June 14, 2010."},{"key":"10.1016\/j.braindev.2018.07.003_b0105","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.rasd.2012.04.002","article-title":"Validation of an interview-based rating scale developed in Japan for pervasive developmental disorders","volume":"6","author":"Ito","year":"2012","journal-title":"Res Autism Spectr Disord"},{"key":"10.1016\/j.braindev.2018.07.003_b0110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpn.2015.12.005","article-title":"Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC","volume":"20","author":"Curatolo","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.braindev.2018.07.003_b0115","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.braindev.2018.07.003_b0120","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.braindev.2018.07.003_b0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40810-015-0004-x","article-title":"Everolimus improves behavioral deficits in a patient with autism associated with tuberous sclerosis: a case report","volume":"1","author":"Ishii","year":"2015","journal-title":"Neuropsychiatr Electrophysiol"},{"key":"10.1016\/j.braindev.2018.07.003_b0130","first-page":"495","article-title":"Reliability and validity of the Pervasive Developmental Disorder (PDD)\u2013Autism Society Japan Rating Scale (PARS): a behavior checklist for adolescent and adults with PDDs","volume":"48","author":"Kamio","year":"2006","journal-title":"Clin Psychiatry (Seishin-Igaku)"},{"key":"10.1016\/j.braindev.2018.07.003_b0135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/ajmg.a.36787","article-title":"Comparative analysis of autistic traits and behavioral disorders in Prader-Willi syndrome and Asperger disorder","volume":"167a","author":"Song","year":"2015","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.braindev.2018.07.003_b0140","first-page":"6","article-title":"Application of the final DSM-5 criteria for young children with autism spectrum disorder","volume":"4","author":"Sumi","year":"2014","journal-title":"Autism Open Access"},{"key":"10.1016\/j.braindev.2018.07.003_b0145","unstructured":"de Vries PJ. The Neuroscience of TSC \u2013 are we at risk of getting lost between the bench and the bedside? International TSC Research Conference: From DNA to Human Therapies; September 23\u201326; Chicago 2009."},{"key":"10.1016\/j.braindev.2018.07.003_b0150","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial","volume":"17","author":"Davies","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.braindev.2018.07.003_b0155","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.braindev.2018.07.003_b0160","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/iju.13168","article-title":"Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: a single institution experience in Japan","volume":"23","author":"Hatano","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.braindev.2018.07.003_b0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13023-017-0581-9","article-title":"Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide","volume":"12","author":"Davies","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2018.07.003_b0170","doi-asserted-by":"crossref","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with tuberous sclerosis complex: Final results from the EXIST-1 study","volume":"11","author":"Franz","year":"2016","journal-title":"PloS One"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760418301761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760418301761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T17:54:01Z","timestamp":1543946041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760418301761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0387760418301761"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2018.07.003","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2018.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V. on behalf of The Japanese Society of Child Neurology.","name":"copyright","label":"Copyright"}]}}